title: Formulation and optimization of a sustained-release tablet of ketorolac tromethamine.
abstract: The objective of our study was to formulate a sustained-release tablet of Ketorolac tromethamine, which is a nonsteroidal anti-inflammatory agent. A 2(3) full factorial design (8 runs) was selected. The variables studied were the amount of drug (30 and 40 mg), ratio of hydroxypropyl methylcellulose (HPMC)/sodium carboxymethylcellulose (NaCMC) (240/40 and 140/140 mg), and amount of ethylcellulose (140 and 180 mg). Swelling-controlled matrix tablets were manufactured by direct compression of formulation ingredients using a Stokes single punch tablet press. Dissolution tests were performed using USP apparatus 3 (Bio-Dis II), at various pHs to mimic the conditions that exist in the gastrointestinal tract. Responses studied included time for 50% of the drug to dissolve (T(50)), diffusional exponent (n) that characterizes the release mechanism, and percent friability of the tablets. Analysis of variance indicated that the release rate (T(50)) was affected by the HPMC/NaCMC ratio, amount of drug, and two-way and three-way interactions; whereas the amount of drug, HPMC/NaCMC ratio, ethylcellulose, and the interaction between drug and HPMC/NaCMC and HPMC/NaCMC and ethylcellulose and also three-way interactions were significantly affecting the diffusional exponent (n). The release mechanism was found to be super-case II transport. The friability of the tablets was significantly affected by all three factors: amount of drug, HPMC/NaCMC ratio, and amount of ethylcellulose. The formulation giving the best release characteristics was identified.
authors.affiliation: Department of Applied Pharmaceutical Sciences, School of Pharmacy, University of Rhode Island, Kingston, Rhode Island 02881, USA.
authors.forename: Neha
authors.initials: N
authors.lastname: Vatsaraj
authors.forename: Hossein
authors.initials: H
authors.lastname: Zia
authors.forename: Thomas
authors.initials: T
authors.lastname: Needham
mesh_terms: D002626:Chemistry, Pharmaceutical; D019245:Compressive Strength; D003692:Delayed-Action Preparations / Q000737:chemistry; D020911:Ketorolac Tromethamine / Q000737:chemistry*; D012995:Solubility; D013607:Tablets
chemical_list: D003692:Delayed-Action Preparations; D013607:Tablets; D020911:Ketorolac Tromethamine